Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression
Pharmaceutics · 09.05.2024 · 16 (5) · 636
DOI: 10.3390/pharmaceutics16050636 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 09.05.2024. Verfasst von Alyona B Kuznetsova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Cancer remains a significant challenge for public healthcare systems worldwide. Within the realm of cancer treatment, considerable attention is focused on understanding the tumor microenvironment (TME)—the complex network of non-cancerous elements surrounding the tumor. Among the cells in TME, tumor-associated macrophages (TAMs) play a central role, traditionally categorized as pro-inflammatory M1 macrophages or anti-inflammatory M2 macrophages. Within the TME, M2-like TAMs can create a protective environment conducive to tumor growth and progression. These TAMs secrete a range of factors and molecules that facilitate tumor angiogenesis, increased vascular permeability, chemoresistance, and metastasis. In response to this challenge, efforts are underway to develop adjuvant therapy options aimed at reprogramming TAMs from the M2 to the anti-tumor M1 phenotype. Such reprogramming holds promise for suppressing tumor growth, alleviating chemoresistance, and impeding metastasis. Nanotechnology has enabled the development of nanoformulations that may soon offer healthcare providers the tools to achieve targeted drug delivery, controlled drug release within the TME for TAM reprogramming and reduce drug-related adverse events. In this review, we have synthesized the latest data on TAM polarization in response to TME factors, highlighted the pathological effects of TAMs, and provided insights into existing nanotechnologies aimed at TAM reprogramming and depletion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia.
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, 119234 Moscow, Russia.
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
- Department of Biological Chemistry, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
ORCID-Profile: Ekaterina P Kolesova, Alessandro Parodi, Andrey A Zamyatnin, Vera S Egorova
Förderung
- Russian Science Foundation
Zitieren
APA
Kuznetsova, A. B., Kolesova, E. P., Parodi, A., Zamyatnin, A. A., & Egorova, V. S. (2024). Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression. Pharmaceutics, 16(5), 636. https://doi.org/10.3390/pharmaceutics16050636
Vancouver
Kuznetsova AB, Kolesova EP, Parodi A, Zamyatnin AA, Egorova VS. Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression. Pharmaceutics. 2024;16(5):636. doi:10.3390/pharmaceutics16050636
BibTeX
@article{Kuznetsova2024,
author = {Kuznetsova, Alyona B and Kolesova, Ekaterina P and Parodi, Alessandro and Zamyatnin, Andrey A and Egorova, Vera S},
title = {Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {5},
pages = {636},
doi = {10.3390/pharmaceutics16050636}
}
EUVIMED